QIAGEN Drives The Development Of Companion Diagnostics With Two Key Appointments
QIAGEN has announced the appointment of two high level members, Dr Pia Garguilo and Richard Watts, to the recently formed Pharma Business Development team.
Read MoreMonth: April 2010
Siemens’ CEO to Join AdvaMed Dx’s Board of Directors
Siemens Healthcare Diagnostics has announced that Donal Quinn has been appointed to AdvaMed Dx’s Board of Directors. Quinn joins an 18-member Board comprised of executives from leading diagnostic companies worldwide.
Read MoreNew Data Indicate Effectiveness of Clarient’s Pulmotax for Lung Cancer
Clarient Inc has announced that data from a new study suggest that the Clarient Insight Dx Pulmotax assay may effectively predict which lung cancer patients will respond favorably to chemotherapy.
Read MoreAltheaDx and Nicholas Conor Institute to Collaborate on Cancer Molecular Diagnostics
AltheaDx and The Nicholas Conor Institute for Pediatric Cancer Research, announced that they have entered into collaboration to develop a broad panel of diagnostic, prognostic, and treatment prediction information for pediatric cancer.
Read MoreBATTLE Links Potential Biomarkers to Drugs for Lung Cancer
The first lung cancer clinical trial to guide targeted therapies to patients based on molecular signatures in tumor biopsies is a step toward personalized care and more effective, efficient clinical trials for new drugs, study leaders reported.
Read More